T2 Biosystems Inc. (NASDAQ:TTOO) traded down 3.6% during mid-day trading on Tuesday . The stock traded as low as $6.95 and last traded at $6.95, with a volume of 128,334 shares trading hands. The stock had previously closed at $7.21.

Several equities research analysts have recently issued reports on the company. Canaccord Genuity lowered their price target on T2 Biosystems from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, August 2nd. Zacks Investment Research downgraded T2 Biosystems from a “hold” rating to a “sell” rating in a research report on Wednesday, July 27th. WBB Securities raised T2 Biosystems from a “buy” rating to a “strong-buy” rating and raised their price target for the company from $11.00 to $12.00 in a research report on Wednesday, July 20th. Leerink Swann reaffirmed a “buy” rating on shares of T2 Biosystems in a research report on Sunday, July 10th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of T2 Biosystems in a research report on Saturday, July 9th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $10.65.

The company’s market capitalization is $169.33 million. The firm’s 50 day moving average is $6.39 and its 200-day moving average is $8.24.

T2 Biosystems (NASDAQ:TTOO) last issued its quarterly earnings results on Monday, August 1st. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.02. The business had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.53 million. During the same quarter in the previous year, the business earned ($0.54) earnings per share. T2 Biosystems’s quarterly revenue was up 75.5% on a year-over-year basis. On average, equities analysts forecast that T2 Biosystems Inc. will post ($2.20) EPS for the current year.

In other T2 Biosystems news, SVP Rahul Dhanda sold 3,589 shares of the business’s stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $8.16, for a total transaction of $29,286.24. Following the sale, the senior vice president now directly owns 3,589 shares of the company’s stock, valued at approximately $29,286.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A hedge fund recently raised its stake in T2 Biosystems stock. Aisling Capital LLC raised its stake in T2 Biosystems Inc. (NASDAQ:TTOO) by 12.2% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,830,992 shares of the company’s stock after buying an additional 307,692 shares during the period. T2 Biosystems comprises 5.3% of Aisling Capital LLC’s portfolio, making the stock its 6th largest position. Aisling Capital LLC owned approximately 13.89% of T2 Biosystems worth $30,971,000 at the end of the most recent quarter.

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).